Patients treated with ProTrans in phase II of the clinical trial

NextCell Pharma AB ("NextCell") hereby announces that they today have reached a significant milestone as they have now initiated the second part of the ProTrans-1 clinical trial. In addition to safety, clinical efficacy is evaluated, e.g. whether the patient's own insulin production improves 12 months after treatment with ProTrans compared to placebo. The phase-II part is randomized, double-blind, placebo-controlled which means that neither the patient nor the doctor knows what treatment the patient is receiving. So far, two patients have undergone treatment. In total, 15 patients will be included in the study, of which ten receive ProTrans and five patients receive placebo.

The first part of the ProTrans-1 study started on November 28th, 2017. During the first weeks of 2018, the first patient underwent extensive clinical examinations and testing in order to, on January 24th, 2018 to become the first human ever to receive an infusion with ProTrans. The first part of the study consisted of a dose escalation phase where a total of nine patients were treated with low, medium and high doses of ProTrans. All patients are followed for 12 months and the first patient who was treated in January 2018 has now been in for their last study visit (first patient, last visit).

After having undergone screening visits and further clinical studies at a baseline visit, two patients have now been randomized and treated in the second part of the study. This is a phase II study where patients are randomized to treatment with either ProTrans (ten patients) or placebo (five patients). The purpose with the Phase II part is to evaluate the clinical efficacy as to whether the patient's own insulin production improves 12 months after treatment with ProTrans compared to placebo. ProTrans is developed as a stem cell therapy for inflammatory and autoimmune diseases.

"I want to thank all the patients who participate, it is great that the interest in being involved is so great," says Mathias Svahn, CEO of NextCell.

Stay up to date with the latest development in NextCell Pharma

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Sofia Fredrikson, CFO

Phone: 08-735 5595

E-mail: info@nextcellpharma.com

www.nextcellpharma.com

About NextCell Pharma AB:

Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.

Subscribe

Documents & Links